Search Ontology:
ChEBI
[4)-beta-D-GlcA-(1->4)-beta-D-GlcA2(or 3)Ac-(1->4)-beta-D-Glc-(1->4)-[(R)-4,6-CH3(COO(-))C-beta-D-Gal3(or 2)OHb-(1->3)-(S)-4,6-CH3(COO(-))C-beta-D-Glc-(1->4)-beta-D-Glc-(1->4)-beta-D-Glc-(1->6)]-alpha-DGlc2(or 3)Ac-(1->]n
- Term ID
- CHEBI:63679
- Synonyms
-
- [4)-beta-D-GlcA-(1->4)-2-O-Ac-beta-D-GlcA-(1->4)-beta-D-Glc-(1->4)-[3-O-(CH3CH(OH)CH2C(O))-(R)-4,6-CH3(COO(-))C-beta-D-Gal-(1->3)-(S)-4,6-CH3(COO(-))C-beta-D-Glc-(1->4)-beta-D-Glc-(1->4)-beta-D-Glc-(1->6)]-2-O-Ac-alpha-DGlc-(1->]n
- [4)-beta-D-GlcpA-(1->4)-beta-D-GlcpA2(or 3)Ac-(1->4)-beta-D-Glcp-(1->4)-[(R)-4,6-CH3(COO(-))C-beta-D-Galp3(or 2)OHb-(1->3)-(S)-4,6-CH3(COO(-))C-beta-D-Glcp-(1->4)-beta-D-Glcp-(1->4)-beta-D-Glcp-(1->6)]-alpha-DGlcp2(or 3)Ac-(1->]n
- [D-GlcA-beta-(1->4)-2-O-Ac-D-GlcA-beta-(1->4)-D-Glc-beta-(1->4)-[3-O-CH3-CH2CH(OH)C(O)-D-Gal-beta-(1->3)-4,6-CH3(COO-)C-D-Glc-beta-(1->4)-D-Glc-beta-(1->4)-D-Glc-beta-(1->6)]-2(or3)-O-Ac-D-Glc-alpha-(1->6)]n
- poly-[4)-beta-D-glucopyranuronosyl-(1->4)-2(or 3)-O-acetyl-beta-D-glucopyranuronosyl-(1->4)-beta-D-glucopyranosyl-(1->4)-[4-O,6-O-[(R)-1-carboxylatoethane-1,1-diyl]-3(or 2)-O-(3-hydroxybutanoyl)-beta-D-galactopyranosyl-(1->3)-4-O,6-O-[(R)-1-carboxylatoeth
- Definition
- A branched polysaccharide acid oxoanion comprised of an octasaccharide repeating unit consisting of a backbone of two glucose and two glucuronic acid residues, and a side chain of three glucose and one galactose residues. The octasaccharide is modified by two pyruvyl and two non-stoichiometric O-acetyl groups, and one non-stoichiometric hydroxybutanoyl group. Note thet the structure shown and its molfile represent only one of the possible substitution patterns.
- References
- Ontology
- ChEBI ( EBI )
- is a type of
-
Phenotype
Phenotype resulting from [4)-beta-D-GlcA-(1->4)-beta-D-GlcA2(or 3)Ac-(1->4)-beta-D-Glc-(1->4)-[(R)-4,6-CH3(COO(-))C-beta-D-Gal3(or 2)OHb-(1->3)-(S)-4,6-CH3(COO(-))C-beta-D-Glc-(1->4)-beta-D-Glc-(1->4)-beta-D-Glc-(1->6)]-alpha-DGlc2(or 3)Ac-(1->]n
Phenotype where environments contain [4)-beta-D-GlcA-(1->4)-beta-D-GlcA2(or 3)Ac-(1->4)-beta-D-Glc-(1->4)-[(R)-4,6-CH3(COO(-))C-beta-D-Gal3(or 2)OHb-(1->3)-(S)-4,6-CH3(COO(-))C-beta-D-Glc-(1->4)-beta-D-Glc-(1->4)-beta-D-Glc-(1->6)]-alpha-DGlc2(or 3)Ac-(1->]n
Phenotype modified by environments containing [4)-beta-D-GlcA-(1->4)-beta-D-GlcA2(or 3)Ac-(1->4)-beta-D-Glc-(1->4)-[(R)-4,6-CH3(COO(-))C-beta-D-Gal3(or 2)OHb-(1->3)-(S)-4,6-CH3(COO(-))C-beta-D-Glc-(1->4)-beta-D-Glc-(1->4)-beta-D-Glc-(1->6)]-alpha-DGlc2(or 3)Ac-(1->]n
Human Disease Model